PRESS RELEASE: Leith Healthcare emerges as an independent pharmaceutical company following management buyout.
June 2024
Leith Healthcare will now operate as a stand-alone pharmaceutical company under the leadership of the existing management team, Managing Director Richard Baderin, and Non-Executive Director Richard Grethe.
As a stand-alone company Leith Healthcare will fully focus on and invest in the formation of partnerships, in-licensing, and product development to launch innovative healthcare brands.
Richard Baderin, Managing Director at Leith Healthcare commented: “We’re extremely excited about the future for Leith Healthcare. We have pipeline of launches of innovative healthcare brands over the next 18 months and bold ambitions for the future. It’s the right time for the company to take this step and we’re grateful to the team at CHASE for their support in establishing Leith Healthcare.”
Graham Hawthorn, CEO at CHASE added: “We’re delighted with how quickly the team at Leith Healthcare have moved the business forward and this MBO will enable them to fully focus on the opportunities identified. We look forward to tracking Leith’s future success whilst CHASE continues to focus on the evolution of our market leading outsourced people-based solutions for the UK life sciences sector.”
About Leith Healthcare
Founded in 2023, Leith Healthcare is a privately owned, forward thinking, UK based pharmaceutical company, specialising in innovative healthcare brands that enhance the quality of life of patients and consumers.
About CHASE
CHASE is the UK’s leading independent provider of outsourced people-based solutions to the life sciences sector, with direct connectivity into the NHS. We’re here to maximise potential for patients, medicines, and our people.